Extended-release buprenorphine injection gives people in treatment for opioid use disorder a way to receive their medication once a month in a clinical office, instead of managing a daily film or tablet at home. If you’ve stabilized on Suboxone and want a simpler routine, or if daily dosing has been the barrier keeping you from staying consistent, this format changes the equation in a meaningful way.
What Extended-Release Buprenorphine Injection Is
Extended-release buprenorphine injection is a subcutaneous shot of buprenorphine that dissolves slowly under the skin over weeks, delivering a steady therapeutic dose without any daily medication to manage. The two FDA-approved formulations are Sublocade, approved in 2017, and Brixadi, approved in 2023. Both contain buprenorphine as the active ingredient. What sets them apart from sublingual films or tablets is the delivery mechanism: instead of absorbing a dose through the lining of your mouth every single day, you receive one injection at a clinic and the medication handles the rest.
The stakes here are real. According to the Maryland Department of Health, opioid overdose deaths in the state exceeded 3,000 in 2022, with fentanyl involved in the vast majority of those deaths. Medications like buprenorphine are the most effective tool available for reducing overdose risk, and anything that makes consistent treatment easier to maintain matters. Extended-release buprenorphine injection removes one of the most common reasons people fall off treatment: the daily burden of managing a medication.
How It Works in the Body
Buprenorphine is a partial opioid agonist, which means it activates the same opioid receptors in the brain that heroin, fentanyl, and prescription painkillers target, but only partially. That partial activation is enough to prevent withdrawal symptoms and reduce cravings without producing the intense euphoria associated with full agonists. Buprenorphine also binds to those receptors with unusually high affinity, meaning it holds on tightly and makes it much harder for other opioids to attach and produce their effects.
The “extended-release” part refers to a polymer depot that forms under the skin at the injection site. Once injected, the formulation solidifies into a small gel mass. As the weeks pass, the polymer breaks down gradually, releasing buprenorphine into surrounding tissue at a controlled rate. The Phase 3 SUBLOCADE trial, which enrolled 476 adults with moderate-to-severe opioid use disorder, demonstrated that subcutaneous buprenorphine injection produced stable plasma concentrations across the entire dosing interval. That matters because sublingual buprenorphine, taken daily, produces peaks after each dose and troughs before the next one. The injectable formulation flattens that curve.
Why Stable Blood Levels Matter
With sublingual buprenorphine, plasma levels rise after you take your dose and drop as the day goes on. Those troughs, the low points before the next dose, are windows when cravings intensify and the temptation to use is highest. A 2019 pharmacokinetic study published in Clinical Pharmacokinetics found that injectable extended-release buprenorphine maintained plasma concentrations within a narrow therapeutic range throughout the month, effectively eliminating the daily fluctuation pattern. In practical terms, there is no “low” point in the day where withdrawal creeps back in and cravings spike. The medication is simply working, consistently, in the background.
The Two FDA-Approved Formulations
Sublocade and Brixadi are both subcutaneous injections of extended-release buprenorphine, both administered at the abdomen, and both designed to eliminate daily dosing. The practical difference is in scheduling flexibility. Sublocade is a monthly injection only. Brixadi offers both a weekly and a monthly option, which gives providers more tools for titration early in treatment.
Sublocade
Sublocade is available in two dose levels: 100 mg and 300 mg. The 300 mg dose is typically used for the first two months of treatment, with some patients continuing at that level and others transitioning to 100 mg for maintenance. Before the first injection, FDA guidelines require at least one week of transmucosal buprenorphine, meaning sublingual films or tablets, to confirm tolerability and establish a stable dose. The injection is given by a trained provider in a clinical setting and takes only a few minutes. After the shot, a small, firm gel depot forms under the skin at the injection site. It is visible and palpable as a soft lump, which is normal and expected. That depot is the medication, dissolving slowly over the course of the month.
If you’re researching what the Sublocade injection process looks like before your first appointment, understanding that the visible lump is the drug working, not a complication, removes a common source of anxiety.
Brixadi
Brixadi, approved by the FDA in 2023, comes in weekly doses of 8 mg, 16 mg, 24 mg, and 32 mg, as well as monthly doses of 64 mg, 96 mg, and 128 mg. The weekly formulation is particularly useful in the early weeks of treatment, when providers want the ability to adjust the dose quickly based on how a patient is responding. Once the right dose is established, patients can transition to the monthly schedule. Like Sublocade, Brixadi is injected subcutaneously in the abdomen by a provider. The clinical trial data submitted for FDA approval demonstrated that weekly Brixadi maintained buprenorphine plasma concentrations within the therapeutic range throughout each dosing interval.
Who Is a Good Candidate
The clearest candidates for extended-release buprenorphine injection are people with moderate-to-severe opioid use disorder who have had trouble maintaining consistent daily dosing. A 2021 study published in JAMA Network Open examined adherence patterns among patients prescribed sublingual buprenorphine and found that nearly 40% reported missing doses regularly, with the most common reasons being schedule disruptions, stigma around daily pharmacy visits, and the mental load of managing medication alongside other recovery demands. Injectable buprenorphine addresses all three of those barriers directly.
Beyond adherence history, people in unstable housing benefit significantly from the injection format because there is no daily medication to store, protect, or worry about losing. People whose jobs or family schedules make a daily routine difficult, individuals who want to stop making daily pharmacy trips, and patients who have already stabilized on Suboxone and want a simpler long-term routine are all well-suited candidates. Maryland Medicaid covers both Sublocade and Brixadi for eligible patients, which means cost is not a barrier for a large portion of the population seeking treatment in the state.
When Extended-Release May Not Be the Right Fit
Extended-release buprenorphine injection is not the right starting point for someone who has never used buprenorphine before. The stabilization period on sublingual medication is a required step, not a formality. It confirms that your body tolerates buprenorphine and allows your provider to identify the right dose before committing to an injectable formulation that will be active for weeks.
Patients who need frequent dose adjustments in early treatment, though Brixadi’s weekly option addresses much of that flexibility, may find the monthly injection limiting at first. Pregnant patients present a separate consideration: clinical guidelines from ACOG continue to recommend sublingual buprenorphine as the preferred formulation during pregnancy, and that guidance should be discussed directly with a provider. None of these situations permanently disqualify extended-release buprenorphine as an option, they simply affect timing.
What to Expect from the Injection Process
The appointment itself is brief. A provider administers the injection subcutaneously into the abdomen using a small needle, and the process takes only a few minutes. Most patients describe mild pressure or a brief stinging sensation at the injection site, and some experience soreness for a day or two afterward. A 2019 patient-reported outcomes study from the SUBLOCADE Phase 3 trial found that injection-site pain was consistently rated as mild on standardized pain scales, with no patients discontinuing treatment due to injection discomfort.
After the injection, a small, firm lump forms under the skin at the site. That lump is the gel depot, and it is entirely expected. Your provider will explain this before the appointment, but knowing it in advance makes the experience less surprising. Post-injection monitoring is brief, typically a short observation period in the clinic before you leave. There is no prolonged recovery and no restrictions on activity afterward.
The First Injection: Stabilization Requirements
Before your first extended-release buprenorphine injection, you need at least seven days on transmucosal buprenorphine, meaning sublingual films or tablets. The FDA established this requirement for Sublocade specifically to ensure that patients have demonstrated tolerability and that cravings and withdrawal symptoms are adequately controlled before switching to an injectable formulation. “Stabilized” in clinical terms means no significant withdrawal symptoms between doses, no severe side effects from the medication, and cravings that are meaningfully reduced. If you’re currently on daily Suboxone and meeting those criteria, you may already qualify for the transition.
Ongoing Injections and Dose Adjustments
After the first injection, follow-up appointments are monthly for Sublocade patients, or weekly transitioning to monthly for patients on Brixadi. At each visit, your provider assesses how the medication is working: whether cravings are controlled, whether any illicit opioid use has occurred, and whether side effects are present. Dose adjustments are possible, moving from 300 mg to 100 mg for Sublocade maintenance, or shifting between weekly and monthly Brixadi schedules, based on those check-ins.
The comparison to daily pharmacy visits or observed dosing programs is significant. Instead of a daily obligation, you have one appointment per month. That shift frees up time and mental space for the other parts of recovery.
How It Compares to Daily Sublingual Buprenorphine
The clearest difference is logistical: one monthly appointment versus a daily medication routine. But the clinical differences are also meaningful. The SUBLOCADE Phase 3 trial, published in The Lancet in 2018, compared monthly injectable buprenorphine against placebo in 504 adults with moderate-to-severe opioid use disorder. Patients receiving the injection showed significantly lower rates of illicit opioid use across the 24-week study period, with 28.4% of urine samples in the 300 mg group testing negative for illicit opioids compared to 2.0% in the placebo group. That is a treatment effect large enough to be unambiguous.
If you’re weighing whether an injection or a daily film is the better long-term approach, understanding how the monthly format affects your routine in concrete terms helps frame that decision.
Adherence and Retention Rates
Retention in treatment is one of the strongest predictors of long-term recovery outcomes. The longer someone stays in treatment without interruption, the more opportunity there is to stabilize housing, address mental health, rebuild employment, and reduce overdose risk. A 2020 analysis published in Drug and Alcohol Dependence found that patients on extended-release injectable buprenorphine had higher 6-month retention rates compared to those on daily sublingual formulations, with the gap driven primarily by the elimination of daily adherence demands.
What this means in practice: staying on treatment for six uninterrupted months is meaningfully different from six months with gaps. Consistent weeks without relapse create the stability that makes everything else in recovery easier to pursue.
Privacy and Stigma Reduction
Daily pharmacy visits for sublingual buprenorphine carry a social weight that many patients feel acutely. A 2020 qualitative study published in Substance Abuse Treatment, Prevention, and Policy documented patient reports of feeling watched, judged, or identified as someone in addiction treatment during routine pharmacy interactions. Monthly clinic appointments are discrete, brief, and occur in a medical setting where the purpose of the visit is self-evident. Removing the daily public-facing aspect of medication pickup matters to many patients and is a legitimate factor in choosing a treatment format.
Insurance Coverage and Cost in Maryland
Maryland Medicaid covers both Sublocade and Brixadi under its pharmacy and medical benefits, typically with prior authorization. Prior authorization requires your provider to document your diagnosis and clinical history, which is standard for any specialty medication. The process is handled by the clinic, not by you. For commercially insured patients, coverage varies by plan, but most major insurers cover at least one extended-release buprenorphine formulation with similar prior authorization requirements.
For uninsured patients, both manufacturers operate patient assistance programs. Indivior, which makes Sublocade, runs a dedicated assistance program that provides the medication at no cost for qualifying patients. Braeburn, the maker of Brixadi, offers a similar support program. The concrete step here is simple: before your first appointment, call the clinic and ask specifically what your insurance covers and whether prior authorization is already in process. Clinics experienced in navigating Sublocade coverage in Maryland handle this coordination routinely and can confirm your eligibility before you arrive.
Co-Occurring Mental Health Conditions and Extended-Release Buprenorphine
The overlap between opioid use disorder and conditions like depression, PTSD, and anxiety is substantial. A 2022 NIDA-funded study examining treatment outcomes in patients with co-occurring OUD and psychiatric disorders found that integrated treatment approaches, combining medication for OUD with mental health services, produced significantly better outcomes than either treatment alone on measures of retention, psychiatric symptom severity, and illicit drug use.
Extended-release buprenorphine injection does not replace mental health treatment. What it does is reduce the daily cognitive and logistical burden that often competes with therapy attendance. When you are not managing a daily medication schedule, worrying about running out of films, or making routine pharmacy trips, you have more capacity to engage with counseling, case management, and other recovery supports. For patients managing depression or PTSD alongside OUD, that reduction in daily friction is clinically meaningful.
Getting Started with Extended-Release Buprenorphine in Maryland
The first step is an intake appointment, which can often be scheduled same-day or next-day at Maryland OUD treatment clinics. Maryland’s Overdose Response Strategy includes a same-day access to buprenorphine policy, which means you do not need to wait weeks to begin treatment. At the intake appointment, a provider reviews your history, confirms your diagnosis, verifies your insurance coverage, and starts the stabilization process on sublingual buprenorphine. After at least one week on that regimen, and once your provider confirms you are stable, the transition to the injection can happen at your next appointment.
Treatment through Maryland locations, including Baltimore, College Park, Linthicum Heights, Nottingham, and Owings Mills, follows this same intake-to-injection pathway. The clinic handles monthly scheduling and insurance coordination, so ongoing treatment does not require you to navigate those logistics independently.
If you’ve been researching where to find a qualified provider for extended-release buprenorphine in Maryland, or want to understand what a structured Sublocade program actually looks like before committing, the most useful next step is a direct conversation with a clinic. The questions you have about your specific insurance, your current medication, or your timeline get answered faster by a provider than by any amount of online research.
Call or request an appointment this week. The stabilization period starts from day one, and so does the clock on getting to your first injection.
What Changes Once You Switch
The shift from daily sublingual buprenorphine to a monthly injection is not dramatic in terms of how you feel on the medication, and that is actually the point. Buprenorphine is still the active ingredient. What changes is the structure of your week. There is no daily pill or film to manage. No prescription to refill. No pharmacy line. No daily reminder that you are on medication for opioid use disorder.
For many people in recovery, that quiet normalization is exactly what was missing from the daily dosing routine. Treatment stops being a daily task and becomes something that is simply handled, once a month, in a brief clinical appointment. That shift does not minimize the work of recovery, but it removes an administrative layer that was consuming energy that belongs elsewhere.
If you are currently stable on Suboxone and wondering whether the injection is the right next step, finding a clinic near you that offers extended-release buprenorphine is straightforward in Maryland. The conversation with a provider about whether you are ready to transition takes less than an appointment to have, and the answer comes from your clinical history, not from a checklist.